Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy

Nakamura et al. (Mon,) studied this question.

www.synapsesocial.com/papers/69ff517bef8139f8ff7754fb — DOI: https://doi.org/10.1253/circrep.cr-20-0062

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology· 2005 · 11,322 citations
2. Left Ventricular Amyloid Deposition in Patients With Heart Failure and Preserved Ejection Fraction· 2014 · 439 citations
3. Combination of Commonly Examined Parameters Is a Useful Predictor of Positive <sup>99 m</sup>Tc-Labeled Pyrophosphate Scintigraphy Findings in Elderly Patients With Suspected Transthyretin Cardiac Amyloidosis· 2019 · 51 citations
4. Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis· 2016 · 296 citations
5. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction· 2015 · 1,144 citations